Triple therapy for chronic hepatitis C: Practical Aspects


Cite item

Full Text

Abstract

The paper considers the practical aspects of antiviral therapy with protease inhibitors, a new group of antiviral agents, by using the clinical cases of treatment in patients with chronic hepatitis C as an example. It gives the general points of triple therapy, including indications for its use in previously untreated and unresponsive patients, and discusses in detail possible adverse events and ways of their prevention and correction.

Full Text

Практические аспекты применения трехкомпонентной терапии при хроническом гепатите С. - Аннотация. В статье на примере клинических случаев лечения пациентов с хроническим гепатитом С рассмотрены практические аспекты применения противовирусной терапии с использованием новой группы антивирусных препаратов - ингибиторов протеаз. Представлены общие положения использования трехкомпонентной терапии, в том числе показания к назначению у ранее нелеченных пациентов и не ответивших на лечение, правила прекращения терапии, а также подробно обсуждены возможные нежелательные явления, способы их профилактики и коррекции.
×

About the authors

I G Bakulin

Email: igbakulin@yandex.ru

A V Kiseleva

References

  1. Perz J., Armstrong G., Farrington L. The contribution of hepatitis B virus and hepatitis C virus infection to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
  2. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavir in compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
  3. Desmond C.P., Roberts S.K., Dudley F. al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13: 311-315.
  4. Sherman M., Shafran S., Burak K. et al. Management of chronic hepatitis C: consensus guedlines in hepatitis C patients. Can J Gastrienterol 2007; 21 (Suppl.): 25-34.
  5. Hadziyannis S.J., Sette H. Jr., Morgan T.R. et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  6. Лопаткина Т.Н. Индивидуализированная противовирусная терапия хронического гепатита С сегодня. Гепатол форум 2011; 4: 15-20.
  7. Jacobson I., Mchutchison J., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  8. Sherman K., Flamm S., Afdhal N. et al. Response- guided teleprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
  9. Zeuzem S., Andreane P., Pol S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  10. Сюткин В.Е. Ингибиторы протеазы: новый шаг на пути к персонализации лечения хронического гепатита С, вызванного вирусом 1 генотипа. Клин фармакол и тер 2012; 1: 11-16.
  11. Poordad F., Mccone J., Bacon B. et al. Boceprevir for antreated chronic HCV genotipe 1 infection. N Engl J Med 2011; 364: 1195-1206.
  12. Bacon B., Gordon S., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotip 1 infection. N Engl J Med 2011; 364: 1207-1217.
  13. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651.
  14. Poynard T., Marcellin P., Lee S. et al. Randomized trial of Interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
  15. Veldt B., Heathcote E., Wedemeyer H. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
  16. Morgan T., Ghany M., Kim H. et al. Sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
  17. Maylin S., Martinot-Peignoux M., Moucari R. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829.
  18. Marcellin P., Boyer N.,Gervais A. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875-881.
  19. Cardoso A.C., Moucari R., Figueirdo-Mendes C. et al. Impact of dence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
  20. Bruno S., Stroffolini T., Colombo M. Sustained virological response to interferon is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
  21. Sarrazin C., Kiefer T., Bartels D. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterolog 2007; 132: 1767-1777.
  22. Kuntzen T., Timm J., Berical A. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment naive patients. Hepatology 2008; 48: 1769-1778.
  23. Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  24. Бурневич Э.З. Новая парадигма индивидуализированной противовирусной терапии хронического гепатита С. Часть 1. Боцепревир в комбинации с пегилированным интерфероном альфа и рибавирином. Гепатол форум 2011; 4: 21-32.
  25. Sulkowski M., Wasserman R., Brooks L. et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infectoin. J Viral Hepat 2004; 11: 243-250.
  26. Martin L.M., Younossi Z.M., Price L.L. et al. The impact of ribavirin-induced anemia on health-related quality of life. 56th annual meeting of the American Association for the Study of Liver Diseases; November 11-15, Abstract 600.
  27. Sulkowski M. S., Shiffman M.L., Afdhal N.H. et al. Hepatitis C virus treatment-related anemia is associated wish higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-1611.
  28. Lai M.Y., Kao J.H., Yang P.M. et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
  29. Бакулин И.Г., Сандлер Ю.Г., Шарабанов А.С. Гематологические нежелательные явления при проведении противовирусной терапии у больных с хроническим гепатитом С. Гепатол форум 2011; 4: 2-14.
  30. Nomura H., Tanimoto H., Kajivara E. et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-1317.
  31. Dieterich D.T., Spivak J.L. Hematologik disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies